
Tecartus
INTRODUCTION Tecartus is a new advanced therapy approved to treat adults with mantle cell lymphoma (MCL)¹. This disease is a lymphatic system cancer. Specifically, it
We are a leading company in the field of research and development of advanced therapies. Although we are a young company in the pharmaceutical industry, we have established a solid reputation for our commitment to quality and efficiency in the conduct of clinical trials.
In conclusion, Geistek Pharmaceuticals is a leading company in the field of drug research and development, with a highly qualified and experienced team and a commitment to ethics and transparency. For these reasons, Geistek is the best choice for conducting a clinical trial.
Throughout the development of a new drug, many entities participate with complementary value propositions and through collaborations that might establish very beneficial synergies for both institutions.
Geistek has agreements with more than 500 investment funds and private investors interested in advanced therapies. In addition, it currently works with a large volume of top-level biotechnological and pharmaceutical companies and research centres that carry out their activity in the design and development of this kind of therapies.
Due to the extensive networking that we have, we consider ourselves a key nexus to give the boost that biotechnological and pharmaceutical companies need in the development of their advanced therapies.
INTRODUCTION Tecartus is a new advanced therapy approved to treat adults with mantle cell lymphoma (MCL)¹. This disease is a lymphatic system cancer. Specifically, it
INTRODUCTION Kymriah (Novartis) is an advanced therapy medicine that belongs to the gene therapyproduct category. It is approved for B-cell acute lymphoblastic leukemia (ALL) in
INTRODUCTION ¹. CARVYKTI™ (ciltacabtagene autoleucel – Johnson & Johnson) was approved by the U.S. Food and Drug Administration (FDA) in February 2022 for the treatment
Cookie | Duración | Descripción |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |